Global Radiopharmaceuticals for Diagnosis Market Growth 2024-2030

Global Radiopharmaceuticals for Diagnosis Market Growth 2024-2030

Diagnostic radiopharmaceuticals are a special class of drugs used in medical imaging diagnosis. These drugs contain radioactive isotopes that can locate and emit radiation signals in specific organs or tissues in the body. Through these signals, doctors can use nuclear medicine imaging equipment (such as single photon emission computed tomography (SPECT) and positron emission tomography (PET)) to detect and evaluate the presence and extent of various diseases, such as cancer, heart disease, thyroid dysfunction, brain disease, etc.

The global Radiopharmaceuticals for Diagnosis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Radiopharmaceuticals for Diagnosis Industry Forecast” looks at past sales and reviews total world Radiopharmaceuticals for Diagnosis sales in 2023, providing a comprehensive analysis by region and market sector of projected Radiopharmaceuticals for Diagnosis sales for 2024 through 2030. With Radiopharmaceuticals for Diagnosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiopharmaceuticals for Diagnosis industry.

This Insight Report provides a comprehensive analysis of the global Radiopharmaceuticals for Diagnosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radiopharmaceuticals for Diagnosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radiopharmaceuticals for Diagnosis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiopharmaceuticals for Diagnosis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiopharmaceuticals for Diagnosis.

United States market for Radiopharmaceuticals for Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Radiopharmaceuticals for Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Radiopharmaceuticals for Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Radiopharmaceuticals for Diagnosis players cover Atom High-tech Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Guangdong Xi'ai Pharmaceutical Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Radiopharmaceuticals for Diagnosis market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Technetium [99mTc] Dithiodithiocarbamate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Pentetate
Strontium [89Sr] Chloride
Iodine [125I] Sealed Seed Source
Sodium Iodide [131I]
Other

Segmentation by Application:
Hospital
Clinic
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Atom High-tech Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
Tianjin Said Biopharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Jubilant Radiopharma
PDRadiopharma Inc.
GE Healthcare Ltd
DOE IP
RadioMedix, Inc.
Lantheus

Key Questions Addressed in this Report

What is the 10-year outlook for the global Radiopharmaceuticals for Diagnosis market?

What factors are driving Radiopharmaceuticals for Diagnosis market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Radiopharmaceuticals for Diagnosis market opportunities vary by end market size?

How does Radiopharmaceuticals for Diagnosis break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.